A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Irinotecan (Camptosar)

Topoisomerase Inhibitor class · 15 generic manufacturers · 35 ANDAs filed at FDA.

First FDA approval1996-06-14
Generic availableYes · 15 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$715,899 in CY2024 Part D spend2K claims · 640 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Irinotecan used for?

Irinotecan is a Topoisomerase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Irinotecan?

Yes. 35 ANDAs filed at FDA, 15 generic manufacturers currently shipping.

How much does my plan pay for Irinotecan?

NADAC pricing data not currently available for this drug.

Is Irinotecan on the FDA shortage list?

Irinotecan has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Topoisomerase Inhibitor2 alternatives in D1
01
Etoposide
Brand: Avopef
Lowest NADAC
5Generic mfrs
$36,955CY24 Part D spend
Compare →
02
Topotecan
Brand: HYCAMTIN
Lowest NADAC
7Generic mfrs
$27,966CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.